|
|
|
prIME Oncology invites you to view exciting news released from the 2010 Oncology Annual Meeting
in Chicago.
|
|
|
 |
|
12 JUNE 2010
|
| |
|
This expert interview with Hagop Kantarjian, MD, from The University of Texas M.D. Anderson Cancer Center in Houston, Texas; Julie Vose, MD, from the University of Nebraska Medical Center in Omaha, Nebraska; and Aristoteles Giagounidis, MD, PhD, from St. Johannes Hospital in Duisburg, Germany, discusses the topics of lymphoma, multiple myeloma, and CML focusing on the following data releases:
#8004: Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy
#8017: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104
#8018: Lenalidomide maintenance after transplantation for myeloma
#8021: Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study
#LBA6500: Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study
#6501: Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year
|
| |
|
Click to view the Expert Interview with Hagop Kantarjian, MD; Julie Vose, MD; and Aristoteles Giagounidis, MD, PhD 
Click here to complete the post-test online |
|
|
|
|
|
|
